Lifesci Capital Has Positive Estimate for MLYS Q3 Earnings

Key Points

• Analysts at Lifesci Capital have revised their Q3 2025 earnings estimates for Mineralys Therapeutics to ($0.69) per share, an improvement from the previous estimate of ($0.83).
• The stock has received mixed ratings, with one "sell," one "hold," and three "buy" ratings, resulting in an average rating of "Hold" and a consensus target price of $32.25.
• Insider activity observed includes significant stock sales by CFO Adam Scott Levy, who sold nearly 60,000 shares, decreasing his ownership by 31.07%.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Investment analysts at Lifesci Capital increased their Q3 2025 earnings estimates for shares of Mineralys Therapeutics in a research note issued to investors on Wednesday, August 13th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($0.69) for the quarter, up from their previous forecast of ($0.83). The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics' Q4 2025 earnings at ($0.71) EPS and FY2025 earnings at ($2.53) EPS.

A number of other research firms have also weighed in on MLYS. Jefferies Financial Group began coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price objective for the company. Guggenheim set a $48.00 price objective on shares of Mineralys Therapeutics and gave the company a "buy" rating in a research note on Wednesday, May 14th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a research note on Wednesday, August 13th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $32.25.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock traded down $0.87 during mid-day trading on Friday, reaching $14.47. The company's stock had a trading volume of 1,173,594 shares, compared to its average volume of 880,427. Mineralys Therapeutics has a 12-month low of $8.24 and a 12-month high of $18.38. The company has a market capitalization of $959.29 million, a P/E ratio of -4.06 and a beta of -0.29. The firm's fifty day moving average price is $14.03 and its two-hundred day moving average price is $13.61.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.12.

Insider Transactions at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total transaction of $884,493.00. Following the completion of the sale, the chief financial officer directly owned 132,934 shares of the company's stock, valued at approximately $1,962,105.84. The trade was a 31.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Malcom Rodman sold 11,365 shares of the business's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $12.93, for a total transaction of $146,949.45. Following the completion of the sale, the insider directly owned 92,891 shares of the company's stock, valued at $1,201,080.63. This represents a 10.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 123,051 shares of company stock valued at $1,776,262. Insiders own 25.56% of the company's stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently modified their holdings of the company. Rafferty Asset Management LLC purchased a new position in shares of Mineralys Therapeutics in the second quarter valued at about $776,000. Man Group plc increased its position in shares of Mineralys Therapeutics by 50.1% in the second quarter. Man Group plc now owns 21,852 shares of the company's stock valued at $296,000 after acquiring an additional 7,293 shares during the period. Balyasny Asset Management L.P. increased its position in shares of Mineralys Therapeutics by 37.8% in the second quarter. Balyasny Asset Management L.P. now owns 205,723 shares of the company's stock valued at $2,783,000 after acquiring an additional 56,450 shares during the period. Bank of America Corp DE increased its position in shares of Mineralys Therapeutics by 78.9% in the second quarter. Bank of America Corp DE now owns 263,356 shares of the company's stock valued at $3,563,000 after acquiring an additional 116,134 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in shares of Mineralys Therapeutics in the second quarter valued at about $688,000. Hedge funds and other institutional investors own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.